This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.
Vaccine Data Propels Stocks: Global Week Ahead
by John Blank
Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.
Positive Developments on COVID-19 Treatment Front
by Zacks Equity Research
Positive Developments on COVID-19 Treatment Front.
Moderna (MRNA) Covid Drug Proves 94.5% Efficacy
by Mark Vickery
The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.
The S&P Hits a New High and the Dow Eyes Its Own 30K Milestone
by David Borun
Stocks continue to rally broadly on more good vaccine news, even as Covid-19 cases and deaths spike.
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch
by Daniel Laboe
There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.
Moderna (MRNA) Surges: Stock Moves 6.5% Higher
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
AstraZeneca's (AZN) Calquence Fails in Coronavirus Study
by Zacks Equity Research
AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.
Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress
by Zacks Equity Research
Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.
Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.
Equilibrium Descends on Mixed Market Indexes: AAPL, DIS & More
by Mark Vickery
The re-balancing from a big rush out of tech into cyclical stocks earlier this week was in play Wednesday.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy
by Kinjel Shah
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.
2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine
by Tirthankar Chakraborty
Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.
Positive News on COVID-19 Vaccine
by Zacks Equity Research
Positive News on COVID-19 Vaccine
Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX
by Mark Vickery
A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View
by Zacks Equity Research
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.
Company News for Oct 30, 2020
by Zacks Equity Research
Companies in The News Are: NFLX, MRNA, IPHI, MRVL, RL.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -37.21% and 103.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.